How tuberculosis bacteria manage errors in protein production
Regulation of mycobacterial adaptive mistranslation
This study is looking at how the tuberculosis bacteria manage mistakes when making proteins, which could help scientists find new ways to make current treatments work better against the infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11101479 on NIH RePORTER |
What this research studies
This research investigates how Mycobacterium tuberculosis, the bacteria that causes tuberculosis, regulates its error rates during protein production, a process known as mistranslation. By understanding this regulation, researchers aim to develop new therapies that can disrupt the bacteria's ability to survive under stress, such as antibiotic treatment. The study employs genetic techniques and small molecule screenings to identify potential drugs that can enhance the effectiveness of existing tuberculosis treatments. This could lead to more effective strategies for managing and treating tuberculosis infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis who may benefit from improved treatment options.
Not a fit: Patients with non-tuberculosis infections or those who do not have a bacterial infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that make tuberculosis more susceptible to existing antibiotics.
How similar studies have performed: Previous research has shown promise in targeting bacterial mistranslation as a therapeutic strategy, suggesting potential for success in this approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Javid, Babak — University of California, San Francisco
- Study coordinator: Javid, Babak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.